moxifloxacin has been researched along with cysteine in 2 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (cysteine) | Trials (cysteine) | Recent Studies (post-2010) (cysteine) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 31 | 0 | 11 |
| 3,157 | 552 | 1,690 | 40,132 | 418 | 11,457 |
| Protein | Taxonomy | moxifloxacin (IC50) | cysteine (IC50) |
|---|---|---|---|
| Excitatory amino acid transporter 1 | Homo sapiens (human) | 376 | |
| Excitatory amino acid transporter 3 | Homo sapiens (human) | 161 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Drlica, K; Singh, A; Zhao, X | 1 |
2 review(s) available for moxifloxacin and cysteine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Fluoroquinolone heteroresistance, antimicrobial tolerance, and lethality enhancement.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Cysteine; Disinfectants; DNA Gyrase; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; NAD; Reactive Oxygen Species; Tuberculosis, Multidrug-Resistant | 2022 |